Premium
Pneumocystis carinii Pneumonia Prophylaxis During Pregnancy
Author(s) -
Connelly Rita T.,
Lourwood David L.
Publication year - 1994
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1002/j.1875-9114.1994.tb02832.x
Subject(s) - pneumocystis carinii , pentamidine , trimethoprim , dapsone , medicine , sulfamethoxazole , pneumonia , pyrimethamine , opportunistic infection , pregnancy , adverse effect , immunology , aids related opportunistic infections , population , human immunodeficiency virus (hiv) , virology , sida , antibiotics , pneumocystis jirovecii , viral disease , microbiology and biotechnology , malaria , biology , chloroquine , environmental health , genetics
The frequency of human immunodeficiency virus (HIV) infection among pregnant womenis increasing. Pneumocystis carinii pneumonia (PCP) is the most common opportunistic infection in HIV‐infected patients, and prophylaxis is an important part of decreasing morbidity. Trimethoprim‐sulfamethoxazole (TMP‐SMX), pentamidine, and dapsone, alone or in combination with pyrimethamine, are the most commonly used drugs for PCP prophylaxis in the nonpregnant HIV‐infected population. Trimethoprim‐sulfamethoxazole, however, has the potential for adverse effects in the fetus. Limited data are available for the other agents administered as prophylaxis of PCP.